Open Access. Powered by Scholars. Published by Universities.®
- Discipline
-
- Amino Acids, Peptides, and Proteins (2)
- Analytical, Diagnostic and Therapeutic Techniques and Equipment (2)
- Biological Phenomena, Cell Phenomena, and Immunity (2)
- Diseases (2)
- Medical Sciences (2)
-
- Medical Specialties (2)
- Neoplasms (2)
- Therapeutics (2)
- Cell Biology (1)
- Cell and Developmental Biology (1)
- Life Sciences (1)
- Nanomedicine (1)
- Nanotechnology (1)
- Nutritional and Metabolic Diseases (1)
- Oncology (1)
- Organic Chemicals (1)
- Pathology (1)
- Physical Sciences and Mathematics (1)
- Polycyclic Compounds (1)
- Respiratory Tract Diseases (1)
Articles 1 - 4 of 4
Full-Text Articles in Chemical Actions and Uses
Fluorescein Loading Of Paa Nanoparticles For Tme Release Studies, Alexia T. Apablaza, Rachel Rigsby
Fluorescein Loading Of Paa Nanoparticles For Tme Release Studies, Alexia T. Apablaza, Rachel Rigsby
Science University Research Symposium (SURS)
pH-responsive nanoparticles are designed to release drugs in the mildly acidic environment of tumors (pH ≈ 6.5) while remaining stable in normal tissue (pH 7.4). In this research, this property will be explored beyond just buffers and will eventually test how upregulated protein and extracellular matrix components found in tumors may impact how these particles perform. The first stage of the project focused on validating a fluorescence-based assay and loading fluorescein into the particles. Fluorescein standard curves were prepared in PBS (pH 7.4) and MES (pH 6.5). Both of the standards (MES and PBS) were highly linear (R² ≥ 0.9988), …
Neovascular Pruning By Ido1 Inhibitors Can Potentiate Immunogenic Cytotoxicity Of Ischemia-Targeted Agents To Synergistically Enhance Anti-Pd-1 Responsiveness, Shih-Chun Shen, Souvik Dey, James B. Duhadaway, Erika Sutanto-Ward, Maurice T. Hampton, Serguei V. Kozlov, George C. Prendergast, Alexander J. Muller
Neovascular Pruning By Ido1 Inhibitors Can Potentiate Immunogenic Cytotoxicity Of Ischemia-Targeted Agents To Synergistically Enhance Anti-Pd-1 Responsiveness, Shih-Chun Shen, Souvik Dey, James B. Duhadaway, Erika Sutanto-Ward, Maurice T. Hampton, Serguei V. Kozlov, George C. Prendergast, Alexander J. Muller
Department of Pathology, Anatomy, and Cell Biology Faculty Papers
BACKGROUND: Strategies for deploying indoleamine 2,3-dioxygenase 1 (IDO1)-targeted therapies for use against cancer have focused on IDO1's role in promoting peripheral immune tolerance that shields tumors from effector T cells. However, preclinical investigation of both primary and metastatic tumor development in the lungs has uncovered a previously unappreciated role for IDO1 in directing a counterregulatory response to interferon (IFN)-γ that realigns the local inflammatory environment to promote tumor neovascularization. Understanding how to therapeutically leverage the ability of IDO1 inhibitors to subvert inflammatory neovascularization within the tumor microenvironment has potential ramifications for future clinical development of these compounds.
METHODS: Pulmonary metastases …
Beyond Checkpoint Inhibitors: The Three Generations Of Immunotherapy, John Schaub, Shou-Ching Tang
Beyond Checkpoint Inhibitors: The Three Generations Of Immunotherapy, John Schaub, Shou-Ching Tang
School of Medicine Faculty Publications
Anti-tumor immunotherapy was rediscovered and rejuvenated in the last two decades with the discovery of CTLA-4, PD-1 and PD-L1 and the roles in inhibiting immune function and tumor evasion of anti-tumor immune response. Following the approval of the first checkpoint inhibitor ipilimumab against CTLA-4 in melanoma in 2011, there has been a rapid development of tumor immunotherapy. Furthermore, additional positive and negative molecules among the T-cell regulatory systems have been identified that that function to fine tune the stimulatory or inhibitory immune cells and modulate their functions (checkpoint modulators). Many strategies are being explored to target macrophages, NK-cells, cytotoxic T-cells, …
High Glucose-Upregulated Pd-L1 Expression Through Ras Signaling-Driven Downregulation Of Ptrh1 Leads To Suppression Of T Cell Cytotoxic Function In Tumor Environment, Chenggang Gao, Jiaoshun Chen, Jianwei Bai, Haoxiang Zhang, Yanyi Tao, Shihong Wu, Hehe Li, Heshui Wu, Qiang Shen, Tao Yin
High Glucose-Upregulated Pd-L1 Expression Through Ras Signaling-Driven Downregulation Of Ptrh1 Leads To Suppression Of T Cell Cytotoxic Function In Tumor Environment, Chenggang Gao, Jiaoshun Chen, Jianwei Bai, Haoxiang Zhang, Yanyi Tao, Shihong Wu, Hehe Li, Heshui Wu, Qiang Shen, Tao Yin
School of Graduate Studies Faculty Publications
Background: Nearly 80% of patients with pancreatic cancer suffer from glucose intolerance or diabetes. Pancreatic cancer complicated by diabetes has a more immunosuppressive tumor microenvironment (TME) and is associated with a worse prognosis. The relationship between glucose metabolism and programmed cell death-Ligand 1 (PD-L1) is close and complex. It is important to explore the regulation of high glucose on PD-L1 expression in pancreatic cancer and its effect on infiltrating immune effectors in the tumor microenvironment. Methods: Diabetic murine models (C57BL/6) were used to reveal different immune landscape in euglycemic and hyperglycemic pancreatic tumor microenvironment. Bioinformatics, WB, iRIP [Improved RNA Binding …